• 1
    Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ, Bagshawe KD. Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 528530.
  • 2
    Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myelo-proliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105112.
  • 3
    Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447449.
  • 4
    Lok ASF, Liang RHS, Chiu EKW, Wong K-L, Chan T-K, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182188.
  • 5
    Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299307.
  • 6
    Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 6869.
  • 7
    Rostoker G, Rosenbaum J, Ben Maadi A, Nedelec G, Deforge L, Vidaud M, et al. Reactivation of hepatitis B virus by corticosteroids in a case of idiopathic nephritic syndrome. Nephron 1990; 56: 224.
  • 8
    Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 13631365.
  • 9
    Waite J, Gilson RJC, Weller IAVD, Lacey CHN, Hambling MH, Hawkins A, et al. Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS 1988; 2: 443448.
  • 10
    Marcellin P, Giostra E, Martinot-Peignoux M, Loriot M-A, Jaegle M-L, Wolf P, et al. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991; 100: 14321434.
  • 11
    Ko W-J, Chou N-K, Hsu R-B, Chen Y-S, Wang S-S, Chu S-H, et al. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area. J Heart Lung Transplant 2001; 10: 865875.
  • 12
    Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 925929.
  • 13
    Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616619.
  • 14
    Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al., NIDDK Liver Transplanation Database. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen Gastroenterology 1997; 113: 16681674.
  • 15
    Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519528.
  • 16
    Yeo W, Zee B, Zhong S, Chan PKS, Wong W-L, Ho WM, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 13061311.
  • 17
    Cheng A-L, Hsiung C-A, Su I-J, Chen P-J, Chang M-C, Tsao C-J, et al., Lymphoma Committee of Taiwan Cooperative Oncology Group (TCOG). Steroid free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. HEPATOLOGY 2003; 37: 13201328.
  • 18
    Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 2001; 80: 549552.
  • 19
    Skrabs C, Muller C, Agis H, Mannhalter C, Jager U. Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 2002; 16: 18841886.
  • 20
    Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
  • 21
    Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627629.
  • 22
    Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189191.
  • 23
    Niscola P, Del Principe MI, Maurillo L, Venditti A, Buccisano F, Piccioni D, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005; 19: 18401841.
  • 24
    Law JK, Ho JK, Hoskins PJ, Erb S, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient;potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 10851089.
  • 25
    Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45: 721724.
  • 26
    Yamagata M, Murohisa T, Tsuchida K, Okamoto Y, Tsunoda S, Nakamura M, et al. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma 2007; 48: 431433.
  • 27
    Hernandez JA, Diloy D, Salat D, del Rio N, Martinez S, Castellvi JM. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 2007; 88: 394395.
  • 28
    Dillon R, Hirschfield GM, Allison ME, Rege KP. Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ 2008; 337: a423.
  • 29
    Flowers MA, Heathcote J, Wanless I, Sherman M, Reynolds WJ, Cameron RG, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990; 112: 381382.
  • 30
    Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS. Safety of disease-modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18: 363368.
  • 31
    Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44: 339342.
  • 32
    Michel M, Duvous C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003; 30: 16241625.
  • 33
    Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686687.
  • 34
    del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10: 701702.
  • 35
    Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50: 163166.
  • 36
    Wendling D, Auge B, Betting D, Lohse A, Le Huede G, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788789.
  • 37
    Dusheiko G, Song E, Bowyer S, Whitcutt M, Maier G, Meyers A, et al. Natural history of hepatitis B virus infection in renal transplant recipients - a fifteen year follow-up. HEPATOLOGY 1983; 3: 330336.
  • 38
    Degos F, Lugassy C, Degott C, Debure A, Carnot F, Thiers V, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology 1988; 94: 151156.
  • 39
    Park SK, Yang WS, Lee YS, Jung HH, Chang JW, Choi HJ, et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001; 16: 22222228.
  • 40
    Terrault N. Management of hepatitis B virus infection in liver transplant recipients: prospects and challenges. Clin Transplant 2000; 14(Suppl. 2): 3943.
  • 41
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination of lamivudine and hepatitis B immune globulin. HEPATOLOGY 1998; 28: 585589.
  • 42
    Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg (-), HBcAb (+), HBIgM(-) organ donors. Transplantation 1995; 59: 230234.
  • 43
    Dodson SF, Issa S, Araya V, Gayowski T, Antonio P, Bijan E, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64: 15821584.
  • 44
    Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7: 5158.
  • 45
    Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494499.
  • 46
    Rokuhara A, Tanaka E, Yagi S, Mizokami M, Hashikura Y, Kawasaki S, et al. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome. J Med Virol 2000; 62: 471478.
  • 47
    Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978; 298: 13791383.
  • 48
    Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. HEPATOLOGY 2003; 37: 11721179.
  • 49
    Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. HEPATOLOGY 2000; 31: 488495.
  • 50
    Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. HEPATOLOGY 1993; 18: 13131318.
  • 51
    Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 10581061.
  • 52
    Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan C-K, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7: 513517.
  • 53
    Castells L, Vargas V, Rodriguez-Frias F, Allende H, Jardi R, Margarit C, et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002; 8: 892900.
  • 54
    Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137: 572576.
  • 55
    Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002; 8: 556561.
  • 56
    Lau GKK, Liang R, Chiu EKW, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 1997; 19: 795799.
  • 57
    Martin BA, Rowe JM, Bouides PA, DiPersio JF. Hepatitis B reactivation following allogeneic bone marrow transplantation: case report and review of the literature. Bone Marrow Transplant 1995; 15: 145148.
  • 58
    Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989; 4: 207208.
  • 59
    Fan FS, Tzeng CH, Yeh HM, Chen PM. Reverse seroconversion of hepatitis B virus infections status after allogeneic bone marrow transplantation from a carrier donor. Bone Marrow Transplant 1992; 10: 189191.
  • 60
    Dhedin N, Douvin C, Kuentz M, Saint Marc MF, Reman O, Rieux C, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation. Transplantation 1998; 66: 616619.
  • 61
    Myers RP, Swain MG, Urbanski SJ, Lee SS. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol 2001; 15: 599603.
  • 62
    Hashino S, Nozawa A, Izumiyama K, Yonezumi M, Chiba K, Kondo T, et al. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 29: 361363.
  • 63
    Hsiao L-T, Chiou T-J, Liu J-H, Chu C-J, Lin Y-C, Chao T-C, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12: 8494.
  • 64
    Dai M-S, Chao T-Y, Kao W-Y, Shyu R-Y, Liu T-M. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769774.
  • 65
    Hui CK, Cheung WW, Au WY, Lie AKW, Zhang H-Y, Yueng Y-H, et al. Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 15971603.
  • 66
    Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 2008; 83: 673675.
  • 67
    Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: 230235.
  • 68
    Tong MJ, Sampliner RE, Govindarajan S, Co RL. Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis. HEPATOLOGY 1987; 7: 713718.
  • 69
    Fattovich G, Brollo L, Alberti A, Realdi G, Pontisso P, Giustina G, et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 1990; 10: 141146.
  • 70
    Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs 2007; 16: 777786.
  • 71
    Davis GL, Hoofnagle JH. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Intern Med 1985; 102: 762765.
  • 72
    De Cock KM, Govindarajan S, Sandford N, Redeker AG. Fatal reactivation of chronic hepatitis B. JAMA 1986; 256: 13291331.
  • 73
    Paredes AH, Lewis JH. Terbinafine-induced autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother 2007; 41: 880884.
  • 74
    Biggar RJ, Goedert JJ, Hoofnagle JH. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med 1987; 316: 630631.
  • 75
    Lazizi Y, Grangeot-Keros L, Delfraissy J-F, Boue F, Dubreuil P, Badur S, et al. Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1. J Infect Dis 1988; 158: 666667.
  • 76
    Vento S, Di Perri G, Garofano T, Concia E, Bassetti D. Reactivation of hepatitis B in AIDS. Lancet 1989; 2: 108109.
  • 77
    Altfeld M, Rockstroh JK, Addo M, Kupfer B, Pult I, Will H, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29: 306309.
  • 78
    Honkoop P, Mann RAD, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995; 346: 11561157.
  • 79
    Lau GK, Yiu HH, Fong DY, Cheng H-C, Au W-Y, Lai LSF, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 17421749.
  • 80
    Hsu C, Hsiung CA, Su I-J, Wang M-C, Lin S-F, Lin T-H, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. HEPATOLOGY 2008; 47: 844853.
  • 81
    Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006; 24: 10031009.
  • 82
    Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15: 89102.
  • 83
    Lau GK, He ML, Fong DY, Bartholomeusz A, Au W-Y, Lie AKW, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic stem cell transplantation. HEPATOLOGY 2002; 36: 702709.
  • 84
    Hui CK, Lie A, Au W-Y, Ma S-Y, Leung Y-H, Zhang H-Y, et al. Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant 2005; 5: 14371445.
  • 85
    Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 5860.
  • 86
    Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004; 99: 23692375.
    Direct Link:
  • 87
    Chan TM, Fang GX, Tang CS, Cheng IKP, Lai KN, Ho SKN. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. HEPATOLOGY 2002; 36: 12461252.
  • 88
    Liaw YF, Leung N, Guan R, Merican I, McCaughan G, Gane E, et al., Asian-Pacific Consensus Update Working Party on Chronic Hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472489.
  • 89
    EASL International Consensus Conference on Hepatitis B. September 13-14, 2002, Geneva Switzerland. Consensus Statement. J Hepatol 2003; 39(Suppl. 1): S1S235.
  • 90
    Lok AS, McMahon BJ. AASLD Practice Guidelines: Chronic hepatitis B. HEPATOLOGY 2007; 45: 507539.
  • 91
    Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public helath management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57(RR-8): 120.